Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2014

01-12-2014 | Research Article

Clinical characteristics and antiretroviral treatment of older HIV-infected patients

Authors: Mercedes Gimeno-Gracia, María José Crusells-Canales, María José Rabanaque-Hernández

Published in: International Journal of Clinical Pharmacy | Issue 6/2014

Login to get access

Abstract

Background The number of Human Immunodeficiency Virus (HIV) patients aged 50 years or over is growing year on year, due to both late diagnoses and the chronicity of the illness. This increase is a new phenomenon. Objective To describe the clinical and epidemiological characteristics of the older HIV infected population and determine if there are differences in antiretroviral treatment between younger and older patients. Setting This study was conducted in the outpatient hospital pharmacy service of a University Hospital in Spain. Method A descriptive study involving HIV infected patients aged 50 years or older who received ambulatory antiretroviral therapy between January and December 2011. Variables related to HIV and to antiretroviral therapy were collected. A comparison of antiretroviral drugs used was made with the populations older and younger than 50 years. Main outcome measure Antiretroviral therapy differences between older and younger HIV-patients. Results 130 patients (20 % of the antiretroviral treated patients) were 50 or over and 77 % of these was aged between 50 and 59. At the time of diagnosis, 50 % suffered an advanced state of disease. At the end of the study period, 58 % had CD4 lymphocyte levels of over 500 cells/mm3 and 90 % had an undetectable viral load. The antiretroviral therapy of the older group that was based on protease inhibitors was used in the 51.5 % of the patients compared with 54.4 % in the younger group. The figures for nonnucleoside reverse transcriptase inhibitors based therapy were 43.8 and 39.8 %, respectively. The older population used treatments that included tenofovir (56.9 vs. 64.8 %, p = 0.105) less frequently and used more treatments that included abacavir (26.9 vs. 19.1 %, p = 0.054) than the under 50′s. Conclusion Half the older HIV-infected patients were diagnosed with an advanced disease and the majority showed a positive response to antiretroviral therapy. There are no statistically significant differences between the frequency of antiretroviral therapy use in older and younger HIV-patients, although older HIV-patients has less often used treatments with tenofovir and more often used treatments with abacavir.
Literature
1.
go back to reference Blanco JR, Caro AM, Pérez-Cachafeiro S, Gutierrez F, Iribarren JA, Gonzalez- Garcia J, et al. HIV infection and aging. AIDS Rev. 2010;12:218–30.PubMed Blanco JR, Caro AM, Pérez-Cachafeiro S, Gutierrez F, Iribarren JA, Gonzalez- Garcia J, et al. HIV infection and aging. AIDS Rev. 2010;12:218–30.PubMed
2.
go back to reference Montaner JSG, Hogg R, Wood E, Kerr T, Tyndal M, Levy A, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of HIV epidemic. Lancet. 2006;368:531–6.PubMedCrossRef Montaner JSG, Hogg R, Wood E, Kerr T, Tyndal M, Levy A, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of HIV epidemic. Lancet. 2006;368:531–6.PubMedCrossRef
3.
go back to reference Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;2(382):1525–33.CrossRef Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;2(382):1525–33.CrossRef
4.
go back to reference The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-Infected patients treated with antiretroviral therapy, 1996–2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96.PubMedCentralCrossRef The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-Infected patients treated with antiretroviral therapy, 1996–2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96.PubMedCentralCrossRef
5.
go back to reference The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individual son combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9.PubMedCentralCrossRef The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individual son combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9.PubMedCentralCrossRef
6.
go back to reference Work Group for the HIV and Aging Consensus Project. Summary report from the human immunodeficiency virus and aging consensus project: Treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc. 2012;60:974–9.CrossRef Work Group for the HIV and Aging Consensus Project. Summary report from the human immunodeficiency virus and aging consensus project: Treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc. 2012;60:974–9.CrossRef
7.
go back to reference Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130–9.PubMedCrossRef Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130–9.PubMedCrossRef
8.
go back to reference Blanco JR, Jarrín I, Vallejo M, Berenguer J, Solera C, Rubio R, et al. Definition of advance age in HIV infection: Looking for an age cut-off. AIDS Res Hum Retroviruses. 2012;28:1000–6.PubMed Blanco JR, Jarrín I, Vallejo M, Berenguer J, Solera C, Rubio R, et al. Definition of advance age in HIV infection: Looking for an age cut-off. AIDS Res Hum Retroviruses. 2012;28:1000–6.PubMed
9.
go back to reference Panel de expertos de GeSIDA y Plan Nacional del Sida. [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)]. Enferm Infecc Microbiol Clin. 2013;31:602–613. Panel de expertos de GeSIDA y Plan Nacional del Sida. [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)]. Enferm Infecc Microbiol Clin. 2013;31:602–613.
10.
go back to reference Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.PubMedCrossRef Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.PubMedCrossRef
11.
go back to reference Önen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, et al. Aging and HIV infection: A comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100–9.PubMedCrossRef Önen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, et al. Aging and HIV infection: A comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100–9.PubMedCrossRef
12.
go back to reference Panel de expertos de Secretaría del Plan Nacional sobre el Sida (SPNS), Sociedad Española de Farmacia Hospitalaria (SEFH), Grupo Estudio del SIDA (GESIDA). [Improving adhesion to antiretroviral treatment]. Farm Hosp. 2008;32:349–357. Panel de expertos de Secretaría del Plan Nacional sobre el Sida (SPNS), Sociedad Española de Farmacia Hospitalaria (SEFH), Grupo Estudio del SIDA (GESIDA). [Improving adhesion to antiretroviral treatment]. Farm Hosp. 2008;32:349–357.
14.
go back to reference Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Ageing with HIV: Medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66:2107–11.PubMedCrossRef Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Ageing with HIV: Medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66:2107–11.PubMedCrossRef
15.
go back to reference Navarro G, Nogueras MM, Segura F, Casabona J, Miro JM, Murillas J, et al. HIV-1 infected patients older than 50 years. PISCIS cohort study. J Infect. 2008;57:64–71.PubMedCrossRef Navarro G, Nogueras MM, Segura F, Casabona J, Miro JM, Murillas J, et al. HIV-1 infected patients older than 50 years. PISCIS cohort study. J Infect. 2008;57:64–71.PubMedCrossRef
16.
go back to reference Oliva J, Galindo S, Vives N, Arrillaga A, Izquierdo A, Nicolau A, et al. Delayed diagnosis of HIV infection in Spain. Enferm Infecc Microbiol Clin. 2010;28:583–9.PubMedCrossRef Oliva J, Galindo S, Vives N, Arrillaga A, Izquierdo A, Nicolau A, et al. Delayed diagnosis of HIV infection in Spain. Enferm Infecc Microbiol Clin. 2010;28:583–9.PubMedCrossRef
17.
go back to reference Díez M, Oliva J, Sánchez J, Vives N, Cevallos C. Izquierdo A [Incidence of new HIV diagnoses in Spain, 2004–2009]. Gac Sanit. 2012;26:107–15.PubMedCrossRef Díez M, Oliva J, Sánchez J, Vives N, Cevallos C. Izquierdo A [Incidence of new HIV diagnoses in Spain, 2004–2009]. Gac Sanit. 2012;26:107–15.PubMedCrossRef
18.
go back to reference Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529–36.PubMedCentralPubMedCrossRef Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529–36.PubMedCentralPubMedCrossRef
19.
go back to reference Ortego C, Huedo-Medina TB, Vejo J, Llorca FJ. Adherence to highly active antiretroviral therapy in Spain. A meta-analysis. Gac Sanit. 2011;25:282–9.PubMedCrossRef Ortego C, Huedo-Medina TB, Vejo J, Llorca FJ. Adherence to highly active antiretroviral therapy in Spain. A meta-analysis. Gac Sanit. 2011;25:282–9.PubMedCrossRef
20.
go back to reference Ibarra O, Ortega L. Survey of the pharmaceutical care situation of the HIV patient in Spain. Farm Hosp. 2008;32:170–7.CrossRef Ibarra O, Ortega L. Survey of the pharmaceutical care situation of the HIV patient in Spain. Farm Hosp. 2008;32:170–7.CrossRef
21.
go back to reference Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV- infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18:S19–25.PubMedCentralPubMedCrossRef Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV- infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18:S19–25.PubMedCentralPubMedCrossRef
Metadata
Title
Clinical characteristics and antiretroviral treatment of older HIV-infected patients
Authors
Mercedes Gimeno-Gracia
María José Crusells-Canales
María José Rabanaque-Hernández
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-0015-x

Other articles of this Issue 6/2014

International Journal of Clinical Pharmacy 6/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine